Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.…
Atossa Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update
Atossa Therapeutics (NASDAQ: ATOS) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 16 employees.
The shares were at 1.595 USD on 20 November 2026, down 87.0% over 52 weeks. Its 52-week range is 1.590 USD to 14.85 USD, and it trades at the bottom of that range.
Its market capitalisation is 15.92M USD.
Atossa Therapeutics reports return on equity of -88.4% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 20.57M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.